These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

536 related articles for article (PubMed ID: 25223574)

  • 1. P2X7 receptor: an emerging target in central nervous system diseases.
    Sperlágh B; Illes P
    Trends Pharmacol Sci; 2014 Oct; 35(10):537-47. PubMed ID: 25223574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. P2X7 Receptors Amplify CNS Damage in Neurodegenerative Diseases.
    Illes P
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32825423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. P2X7 receptors: channels, pores and more.
    Volonté C; Apolloni S; Skaper SD; Burnstock G
    CNS Neurol Disord Drug Targets; 2012 Sep; 11(6):705-21. PubMed ID: 22963440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The purinergic P2X7 receptor as a potential drug target to combat neuroinflammation in neurodegenerative diseases.
    Calzaferri F; Ruiz-Ruiz C; de Diego AMG; de Pascual R; Méndez-López I; Cano-Abad MF; Maneu V; de Los Ríos C; Gandía L; García AG
    Med Res Rev; 2020 Nov; 40(6):2427-2465. PubMed ID: 32677086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Motor neuron dysfunction in a mouse model of ALS: gender-dependent effect of P2X7 antagonism.
    Cervetto C; Frattaroli D; Maura G; Marcoli M
    Toxicology; 2013 Sep; 311(1-2):69-77. PubMed ID: 23583883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging role of P2X7 receptors in CNS health and disease.
    Tewari M; Seth P
    Ageing Res Rev; 2015 Nov; 24(Pt B):328-42. PubMed ID: 26478005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. P2X7 antagonists as potential therapeutic agents for the treatment of CNS disorders.
    Chrovian CC; Rech JC; Bhattacharya A; Letavic MA
    Prog Med Chem; 2014; 53():65-100. PubMed ID: 24418608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. P2X7 receptor antagonists: a patent review (2010-2015).
    Park JH; Kim YC
    Expert Opin Ther Pat; 2017 Mar; 27(3):257-267. PubMed ID: 27724045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Involvement of microglial P2X7 receptors and downstream signaling pathways in long-term potentiation of spinal nociceptive responses.
    Chu YX; Zhang Y; Zhang YQ; Zhao ZQ
    Brain Behav Immun; 2010 Oct; 24(7):1176-89. PubMed ID: 20554014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The P2X7 receptor: A main player in inflammation.
    Adinolfi E; Giuliani AL; De Marchi E; Pegoraro A; Orioli E; Di Virgilio F
    Biochem Pharmacol; 2018 May; 151():234-244. PubMed ID: 29288626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Purinergic Signalling and Neurological Diseases: An Update.
    Burnstock G
    CNS Neurol Disord Drug Targets; 2017; 16(3):257-265. PubMed ID: 27658510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. P2X7 receptors in the central nervous system.
    Miras-Portugal MT; Ortega F; Gómez-Villafuertes R; Gualix J; Pérez-Sen R; Delicado EG
    Biochem Pharmacol; 2021 May; 187():114472. PubMed ID: 33587917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The P2X7 receptor channel: recent developments and the use of P2X7 antagonists in models of disease.
    Bartlett R; Stokes L; Sluyter R
    Pharmacol Rev; 2014 Jul; 66(3):638-75. PubMed ID: 24928329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. P2X7 receptor inhibition ameliorates dendritic spine pathology and social behavioral deficits in Rett syndrome mice.
    Garré JM; Silva HM; Lafaille JJ; Yang G
    Nat Commun; 2020 Apr; 11(1):1784. PubMed ID: 32286307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The P2X7 purinergic receptor: An emerging therapeutic target in cardiovascular diseases.
    Chen Z; He L; Li L; Chen L
    Clin Chim Acta; 2018 Apr; 479():196-207. PubMed ID: 29366837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A current review on P2X7 receptor antagonist patents in the treatment of neuroinflammatory disorders: a patent review on antagonists.
    Soni S; Lukhey MS; Thawkar BS; Chintamaneni M; Kaur G; Joshi H; Ramniwas S; Tuli HS
    Naunyn Schmiedebergs Arch Pharmacol; 2024 Jul; 397(7):4643-4656. PubMed ID: 38349395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-Activity Relationships and Therapeutic Potential of Purinergic P2X7 Receptor Antagonists.
    El Idrissi IG; Podlewska S; Abate C; Bojarski AJ; Lacivita E; Leopoldo M
    Curr Med Chem; 2024; 31(11):1361-1403. PubMed ID: 37013427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The phenothiazine-class antipsychotic drugs prochlorperazine and trifluoperazine are potent allosteric modulators of the human P2X7 receptor.
    Hempel C; Nörenberg W; Sobottka H; Urban N; Nicke A; Fischer W; Schaefer M
    Neuropharmacology; 2013 Dec; 75():365-79. PubMed ID: 23954492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Possible Causal Involvement of Neuroinflammatory, Purinergic P2X7 Receptors in Psychiatric Disorders.
    Zhang Y; Yin HY; Rubini P; Tang Y; Illes P
    Curr Neuropharmacol; 2022; 20(11):2142-2155. PubMed ID: 35236262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of P2X7 receptor expression and function in the brain.
    Jimenez-Mateos EM; Smith J; Nicke A; Engel T
    Brain Res Bull; 2019 Sep; 151():153-163. PubMed ID: 30593878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.